The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 18, 2020

Filed:

Apr. 08, 2015
Applicants:

Prothena Bioscience Limited, Dublin, IE;

Hoffmann-la Roche Inc., Little Falls, NJ (US);

Inventors:

Robin Barbour, Walnut Creek, CA (US);

Kate Dora Games-Thiel, Belmont, CA (US);

Tarlochan S. Niijar, Orinda, CA (US);

Wagner Zago, San Mateo, CA (US);

Olaf Mundigl, Weilheim, DE;

Jens Niewoehner, Munich, DE;

Georg Tiefenthaler, Sindelsdorf, DE;

Assignees:

Prothena Bioscience Limited, Dublin, IE;

Hoffmann-LaRoche Inc., Little Falls, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 5/12 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2881 (2013.01); C07K 16/18 (2013.01); C07K 16/28 (2013.01); C12N 5/12 (2013.01); G01N 33/6896 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/35 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2319/33 (2013.01); C07K 2319/74 (2013.01); C12N 2510/02 (2013.01); G01N 2333/47 (2013.01); G01N 2800/28 (2013.01); G01N 2800/50 (2013.01);
Abstract

The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).


Find Patent Forward Citations

Loading…